Navigation Links
Vaccine Against the Chikungunya Virus in Development by a Public-Private Partnership
Date:2/4/2009

LEIDEN, The Netherlands, February 4 /PRNewswire/ -- Top Institute Pharma (TI Pharma) has formed a consortium with Wageningen University, Erasmus University Medical Centre and Nobilon, a subsidiary of Schering-Plough, to develop a 'proof of concept' vaccine against the Chikungunya virus. This vaccine aims to reduce the rate of Chikungunya infections.

Viral disease epidemics have increased in incidence around the world in recent decades. One of these diseases is caused by the Chikungunya virus, which is transmitted by mosquitoes. Originally, the disease was confined to Africa, but later spread to countries in Asia. Several cases of this disease have now been confirmed in various European countries. It appears to be spread by travelers returning from affected countries. In France, there have been more than one hundred cases and in Italy a few hundred. It seems evident that the mosquitoes able of transmitting this disease are also present in Europe. Whether or not the virus will spread further throughout Europe remains to be seen.

Virologist Ab Osterhaus, one of the research supervisors, says: "Considering the increasing spread of the Chikungunya virus in Asia, and probably also in Europe in the future, it is important to develop a vaccine against this virus that can be used not only to protect people living in the endemic area, but also travelers traveling to those areas.

The groups that are going to work together in this project have extensive expertise in the field of exotic viral infectious diseases as well as significant experience with the newest technologies in the field of vaccine development."

This TI Pharma project has a budget of EUR 2.3 million and aims to achieve a 'proof of concept' vaccine by the year 2012.

Chikungunya is a serious viral illness, which is transmitted by the Asian tiger mosquito. The disease causes a sudden high fever, a rash and intense joint pain, which can result in disability, which can last several months. There is currently no vaccine or treatment available to combat this disease.


'/>"/>
SOURCE TI Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Anthrax vaccine produces immunity with nanoparticles, not needles
5. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
6. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
7. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. New nanoparticle vaccine is more effective but less expensive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, ... in analytical testing are being attributed to new regulatory requirements for all new ...
(Date:10/11/2017)... ... ... wash is a basic first aid supply for any work environment, but most personal eye ... first if a dangerous substance enters both eyes? It’s one less decision, and likely quicker ... eye piece. , “Whether its dirt and debris, or an acid or alkali, getting anything ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building ... corporate rebranding initiative announced today. The bold new look is part of a ... company moves into a significant growth period. , It will also expand its service ...
Breaking Biology Technology:
(Date:6/23/2017)... and ITHACA, N.Y. , June ... Cornell University, a leader in dairy research, today announced ... designed to help reduce the chances that the global ... onset of this dairy project, Cornell University has become ... Sequencing the Food Supply Chain, a food safety initiative ...
(Date:5/6/2017)... May 5, 2017 RAM Group ... a new breakthrough in biometric authentication based on ... mechanical properties to perform biometric authentication. These new sensors ... material created by Ram Group and its partners. This ... transportation, supply chains and security. Ram Group is ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
Breaking Biology News(10 mins):